June 3rd, 2021Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer Center (mskcc.org) Transcript: Barbra Rothschild:...

May 26th, 2021Targeted Cancer Therapies ON THIS PAGE What are targeted cancer therapies? How are targets for targeted cancer therapies identified? How are targeted therapies developed? What types of targeted therapies are available? ...

May 25th, 2021Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The link is listed below as well as the transcript. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer...

May 16th, 2021 SAN DIEGO, Nov. 11, 2020 /PRNewswire/ --InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of...

May 8th, 2021[gallery] This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My...

May 7th, 2021November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in...

May 7th, 2021Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year

April 30th, 2021 Elena Cojocaru, Christopher Wilding, Bodil Engelman, Paul Huang & Robin L. Jones Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? |...